Medimpact

# STANDARD COMMERCIAL DRUG FORMULARY PRIOR AUTHORIZATION GUIDELINES

## CELECOXIB

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
CELECOXIB	ELYXYB		48006	GPI-10	
				(6760403000)	

#### **GUIDELINES FOR USE**

- 1. Is the request for the acute treatment of migraine and the patient meets **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - The patient had a trial of generic celecoxib AND OTC or generic aspirin, diclofenac, ibuprofen, or naproxen
  - The patient is unable to swallow pills (e.g., tablets or capsules)

If yes, approve for 6 months by GPID or GPI-14 with a quantity limit of #38.4 mL per 30 days.

If no, do not approve.

DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **CELECOXIB** (Elyxyb) requires the following rule(s) be met for approval:

- A. The request is for the acute (quick onset) treatment of migraines
- B. You are 18 years of age or older
- C. You had a trial of generic celecoxib AND over-the-counter (OTC) or generic aspirin, diclofenac, ibuprofen, or naproxen
- D. You are unable to swallow pills (such as tablets or capsules)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

## RATIONALE

For further information, please refer to the Prescribing Information and/or Drug Monograph for Elyxyb.

## REFERENCES

 Elyxyb [Prescribing Information]. Raleigh, NC: BioDelivery Sciences International, Inc.; September 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A Commercial Effective: 04/01/22 Created: 02/22 Client Approval: 02/22

P&T Approval: 01/22

Copyright © 2022 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.